Literature DB >> 1312896

p53 mutations in human lung tumors.

C W Miller1, K Simon, A Aslo, K Kok, J Yokota, C H Buys, M Terada, H P Koeffler.   

Abstract

Mutation of one p53 allele and loss of the normal p53 allele [loss of heterozygosity (LOH)] occur in many tumors including lung cancers. These alterations apparently contribute to development of cancer by interfering with the tumor suppressor activity of p53. We directly sequenced amplified DNA in the mutational hot spots (exons 4-8) of p53 in DNA samples from 40 lung cancers. Most (31 of 40) samples were preselected for LOH in the region of p53. We detected 23 p53 mutations within these exons in 22 lung cancers; no p53 mutations were found in normal tissue of the patients. One-half of the mutations were G to T transversions on the nontranscribed strand, consistent with mutagenesis by tobacco smoke. Mutations of C to A on the nontranscribed strand, which would result from G to T mutations on the transcribed strand, were detected only in one sample. Three of 23 mutations were nonsense mutations; to date, nonsense mutations of p53 have not been reported in lung cancer. Mutation of this p53-coding region was detected in 20 of 27 small cell lung cancer samples, representing a 70% occurrence. Mutation of the p53 gene is apparently very frequent in small cell lung cancers. When LOH in the p53 region could be determined, complete concordance occurred between a sample having both a p53 mutation and LOH in the region of p53 (18 of 18 samples). Twelve samples of lung cancer had LOH in the region of p53, but the samples had no detectable p53 mutations, suggesting either alterations outside the known mutational hot spots of p53 or alterations of another unidentified tumor suppressor gene in the region of p53.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312896

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Targeting Rb inactivation in cancers by synthetic lethality.

Authors:  Gabriel M Gordon; Wei Du
Journal:  Am J Cancer Res       Date:  2011-06-30       Impact factor: 6.166

2.  Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab.

Authors:  M Hardy-Werbin; O Arpí; A Taus; P Rocha; D Joseph-Pietras; L Nolan; S Danson; R Griffiths; M Lopez-Botet; A Rovira; J Albanell; C H Ottensmeier; E Arriola
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

3.  Specificity of polymerase chain reaction monoclonality for diagnosis of gastric mucosa-associated lymphoid tissue (MALT) lymphoma: direct comparison to Southern blot gene rearrangement.

Authors:  A P Weston; S K Banerjee; R T Horvat; R Cherian; D R Campbell; M N Zoubine
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

4.  Exposure of organ cultures from human tracheal epithelium to chemical carcinogens and subsequent long-term co-cultivation with autologous isotopic fibroblasts.

Authors:  I Haas; P Koldovsky; U Ganzer
Journal:  Eur Arch Otorhinolaryngol       Date:  1996       Impact factor: 2.503

5.  Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival.

Authors:  Miho Kono; Pamela K Allen; Steven H Lin; Xiong Wei; Melenda D Jeter; James W Welsh; James D Cox; Ritsuko Komaki
Journal:  J Thorac Oncol       Date:  2017-08-10       Impact factor: 15.609

6.  Cytotoxic susceptibility and defective MHC class I expression do not correlate with mutation of p53 in human carcinomas.

Authors:  Z Végh; P Wang; F Vánky; C Hising; K Sjöwall; B Larsson; E Klein
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

7.  Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization.

Authors:  G Sauter; G Deng; H Moch; R Kerschmann; K Matsumura; S De Vries; T George; J Fuentes; P Carroll; M J Mihatsch
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

8.  P53 mutations in urinary bladder cancer patients from Central Poland.

Authors:  Edyta Borkowska; Aleksandra Binka-Kowalska; Maria Constantinou; Agnieszka Nawrocka; Józef Matych; Bogdan Kałuzewski
Journal:  J Appl Genet       Date:  2007       Impact factor: 3.240

9.  Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Authors:  Lauren Averett Byers; Jing Wang; Monique B Nilsson; Junya Fujimoto; Pierre Saintigny; John Yordy; Uma Giri; Michael Peyton; You Hong Fan; Lixia Diao; Fatemeh Masrorpour; Li Shen; Wenbin Liu; Boris Duchemann; Praveen Tumula; Vikas Bhardwaj; James Welsh; Stephanie Weber; Bonnie S Glisson; Neda Kalhor; Ignacio I Wistuba; Luc Girard; Scott M Lippman; Gordon B Mills; Kevin R Coombes; John N Weinstein; John D Minna; John V Heymach
Journal:  Cancer Discov       Date:  2012-09-06       Impact factor: 39.397

10.  Infrequent mutation of the tumour-suppressor gene Smad4 in early-stage colorectal cancer.

Authors:  C Mamot; G Mild; J Reuter; U Laffer; U Metzger; L Terracciano; J-L Boulay; R Herrmann; C Rochlitz
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.